Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Verrica Pharmaceuticals Inc. | vrca-ex321_11.htm |
| EX-31.2 - EX-31.2 - Verrica Pharmaceuticals Inc. | vrca-ex312_7.htm |
| EX-31.1 - EX-31.1 - Verrica Pharmaceuticals Inc. | vrca-ex311_6.htm |
| EX-10.20 - EX-10.20 - Verrica Pharmaceuticals Inc. | vrca-ex1020_365.htm |
| EX-10.19 - EX-10.19 - Verrica Pharmaceuticals Inc. | vrca-ex1019_363.htm |
| EX-10.18 - EX-10.18 - Verrica Pharmaceuticals Inc. | vrca-ex1018_364.htm |
| EX-4.1 - EX-4.1 - Verrica Pharmaceuticals Inc. | vrca-ex41_229.htm |
| 10-K - 10-K - Verrica Pharmaceuticals Inc. | vrca-10k_20191231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Verrica Pharmaceuticals Inc.:
We consent to the incorporation by reference in the registration statements (Nos. 333-226153 and 333-231265) on Form S-8 of Verrica Pharmaceuticals Inc. of our report dated March 13, 2020, with respect to the balance sheets of Verica Pharmaceuticals Inc. as of December 31, 2019 and 2018, and the related statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity (deficit) and cash flows for the years then ended, and the related notes, which report appears in the December 31, 2019 annual report on Form 10-K of Verrica Pharmaceuticals Inc.
/s/ KPMG LLP
Philadelphia, Pennsylvania
March 13, 2020